Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.

ABSTRACT:

Background

Myeloid-derived suppressor cells (MDSC), a cornerstone of cancer-related immunosuppression, influence response to therapy and disease outcomes in melanoma patients. Nevertheless, their quantification is far from being integrated into routine clinical practice mostly because of the complex and still evolving phenotypic signatures applied to define the cell subsets. Here, we used a multistep downsizing process to verify whether a core of few markers could be sufficient to capture the prognostic potential of myeloid cells in peripheral blood mononuclear cells (PBMC) of metastatic melanoma patients.

Methods

In baseline frozen PBMC from a total of 143 stage IIIc to IV melanoma patients, we first assessed the relevant or redundant expression of myeloid and MDSC-related

SUBMITTER: Huber V 

PROVIDER: S-EPMC7887358 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature